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Introduction: The cytochrome P450 (CYP) enzymes are a class of heme-containing enzymes involved in phase I
metabolism of a large number of xenobiotics. The CYP family member CYP2E1 metabolises many xenobiotics and
pro-carcinogens, it is not just expressed in the liver but also in many other tissues such as the kidney, the lung, the
brain, the gastrointestinal tract and the breast tissue. It is induced in several pathological conditions including can-
cer, obesity, and type II diabetes implying that this enzyme is implicated in other biological processes beyond its
role in phase I metabolism. Despite the detailed description of the role of CYP2E1 in the liver, its functions in other
tissues have not been extensively studied. In this study, we investigated the functional significance of CYP2E1 in
breast carcinogenesis.
Methods: Cellular levels of reactive oxygen species (ROS) were measured by H2DCFDA (2 2.9.2 2′,7′-
dichlorodihydrofluorescein diacetate) staining and autophagy was assessed by tracing the cellular levels of
autophagy markers using western blot assays. The endoplasmic reticulum stress and the unfolded protein response
(UPR) were detected by luciferase assays reflecting the splicing of mRNA encoding the X-box binding protein
1 (XBP1) transcription factor and cell migration was evaluated using the scratch wound assay. Gene expression was
recorded with standard transcription assays including luciferase reporter and chromatin immunoprecipitation.
Results: Ectopic expression of CYP2E1 induced ROS generation, affected autophagy, stimulated endoplasmic
reticulum stress and inhibited migration in breast cancer cells with different metastatic potential and p53 status.
Furthermore, evidence is presented indicating that CYP2E1 gene expression is under the transcriptional control of
the p53 tumor suppressor.
Conclusions: These results support the notion that CYP2E1 exerts an important role in mammary carcinogenesis,
provide a potential link between ethanol metabolism and breast cancer and suggest that progression, and
metastasis, of advanced stages of breast cancer can be modulated by induction of CYP2E1 activity.Introduction
Cytochrome P450 (CYP450) is a superfamily of hemo-
proteins essential for the biotransformation of drugs [1].
They are mainly localised in the liver, participating in
the phase I metabolism of a wide range of exogenous
compounds and the biosynthesis and metabolism of en-
dogenous hormones [2]. Apart from the liver, CYPs are
also expressed in other tissues such as lung, kidney and* Correspondence: cdemonacos@manchester.ac.uk
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reproduction in any medium, provided the orhematopoietic tissue [3], and specific isoenzymes of the
superfamily have been identified in tumours [4] where
they are suggested to affect the response to anticancer
therapy [4,5]. CYP450s are highly conserved across spe-
cies implying that, in addition to their function in the
metabolism of xenobiotics, these enzymes possibly exert
broader physiological functions [6]. Consistent with this
view, the CYP2E1 isoenzyme has been implicated in a
variety of pathological conditions such as diabetes, non-
alcoholic steatohepatitis (NASH) and cancer, possibly asLtd. This is an open access article distributed under the terms of the Creative
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oxygen species (ROS) [7].
CYP2E1 metabolizes several small molecules such as
ethanol, acetaminophen and pro-carcinogens like nitrosa-
mines and azo compounds [3]. CYP2E1-mediated metab-
olism of these compounds generates toxic intermediates
and excessive amounts of ROS [7]. High ROS levels, and
hence oxidative stress due to increased CYP2E1 protein
levels and induced enzymatic activity, are the main causes
of various liver diseases associated with chronic alcohol
consumption [8] and a variety of other pathophysiological
conditions including diabetes type II and obesity [9].
Since CYP2E1 is a key determinant of the cellular
redox state generating free radicals in a non-specific
manner, even in the absence of a substrate the gene ex-
pression of this enzyme is tightly regulated [10]. Indeed,
links between CYP2E1 protein levels and cytokines ac-
tivity have been shown in recent reports [11] as well as
variable CYP2E1 gene expression in numerous inflam-
matory diseases including cancer [12,13]. Autophagy is
one of the pathways induced by elevated ROS levels
which triggers the accumulation of various autophagy-
regulated genes (ATGs) including beclin-1 and the light
chain 3 (LC3) [14], thereby stimulating the formation of
the autophagosome in cancer [15,16].
Furthermore, oxidative stress and other cellular ten-
sions, such as DNA damage and viral infection, impair the
protein-folding process resulting in the accumulation of
misfolded proteins within the endoplasmic reticulum (ER)
lumen [17], stimulating the initiation of the unfolded pro-
tein response (UPR) [18]. UPR takes place in the ER
lumen and is a major signal transduction pathway aiming
to alleviate ER stress by removing accumulated unfolded
proteins from this cellular compartment [18].
Clinical studies have indicated that stage I breast tu-
mours express higher CYP2E1 mRNA levels compared to
stages II, III and IV [19]. Taken together, the differential
expression of CYP2E1 in different tumours and various
stages of breast cancer, with its capacity to induce ROS
production [7], raises the questions whether CYP2E1 cel-
lular levels could be an indicator of breast cancer progres-
sion and which are the factors involved in its differential
regulation of gene expression in the various stages of
breast cancer. Here we present evidence to suggest that
ectopically expressed CYP2E1-mediated oxidative stress
regulates autophagy, ER stress and migratory potential
and its gene expression is regulated by the p53 tumour
suppressor in a cell-type-dependent manner in breast can-
cer cells.
Methods
Cell lines, cell culture and constructs
The human breast carcinoma cell lines MCF7 (p53+/+)
[20], T47D (mutated p53) [20], MDA-MB-231 (mutatedp53) [20,21] and MDA-MB-157 (p53-/-) [20] (obtained
from the European Collection of Cell Cultures (ECACC))
were maintained in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich, Gillingham, UK), supplemented with
10% foetal bovine serum (Gibco, Paisley, UK) and 1%
penicillin/streptomycin (Lonza, Allendale, NJ, USA) at
37°C in a humidified atmosphere containing 5% CO2.
Cells were treated with 10 μM etoposide (Sigma-Aldrich)
for 16 hours, 500 μM N-acetylcysteine (NAC) (Sigma-
Aldrich) for 16 hours, 2.5 mM acetaminophen (APAP)
(Sigma-Aldrich) for 3 h, 20 μM chlormethiazole
(CMZ) (Sigma-Aldrich) for 16 h, 1 μM bortezomib
(Bort) (Selleckchem, Stratech Scientific Ltd., Newmarket,
UK) the MCF7 for 24 and the MDA-MB-231 cells for 8 h
and 100 mM ethanol for either 24 or 2 h as indicated in
the figure legends. Transient transfections were carried
out using the polyfect transfection reagent (Qiagen,
Crawley, UK), according to the manufacturer’s instruc-
tions. Constructs used for ectopic expression included
PCDNA3 [22,23], and β-galactosidase [22,23]. Human
CYP2E1 luciferase reporter containing putative p53 bind-
ing sites was constructed by amplifying the upstream re-
gion of the CYP2E1 promoter -7873 to -5896 (counted
from the translation initiation site) and inserting it in the
pGL3 promoter luciferase vector (Promega, Madison, WI,
USA). CYP2E1 short hairpin RNA (shRNA) P-silencer
was synthesised using the P-silencer 2.1-U6 hygro vector
(Agilent Technologies, Wokingham, UK). Dr. Cederbaum
(Mount Sinai School of Medicine, New York) kindly
provided the CYP2E1 cDNA. The pCAX-HA-2xXBP1
deltaDBD9anATG)-Luc-F luciferase reporter [24] is a gen-
erous gift from Dr. Iwawaki (Frontier Research System,
Riken, Japan).Immunoblotting and antibodies
High-salt lysis buffer (50 mM Tris-HCl pH 7.5,
400 mM NaCl, 5 mM ethylenediaminetetraacetic acid
(EDTA) pH 8, 0.5% NP-40, 1% Triton X-100, 1 mM di-
chlorodiphenyltrichloroethane (DDT), 1 mM phenyl-
methylsulphonyl fluoride (PMSF) and 1 μg/ml protease
inhibitor cocktail (pepstatin, aprotinin, and leupeptin))
was used to harvest cells. After SDS-PAGE and electro-
blotting membranes were incubated with anti-CYP2E1
(Abcam, Cambridge, UK, ab28146), anti-p53 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA, sc-126), anti-β-
actin (Abcam, 8227), anti-LC-3 (Cell Signaling Tech-
nologies, Beverly, MA, USA, 4108S), anti-beclin-1 (Cell
Signaling Technologies, 3495S), anti-Atg5 (Cell Signaling
Technologies, 2630S), anti-Atg7 (Cell Signaling Technolo-
gies, 2631S), anti-CCAAT/enhancer-binding protein
(C/EBP) homologous protein (CHOP) (Cell Signaling
Technologies, 2895S), and anti-GRP78 (Santa Cruz Bio-
technology, sc-376768) antibodies.
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(H2DCFDA) staining
Cells were transiently transfected with the indicated con-
structs and 16 h after transfection dissociated from the
plates and centrifuged at 1,200 rpm for 3 mins. Cells
were then incubated with 1 ml of APC-H7-conjugated
CD20 antibody (BD Biosciences, Franklin Lakes, NJ,
USA, 641396) where indicated, washed three times with
PBS, incubated with H2DCFDA (Invitrogen, Carlsbad,
CA, USA, D399) in the dark at 37°C for 30 min and sub-
jected to fluorescence-activated cell sorting (FACS) ana-
lysis using CYAN-ADP flow cytometer (Dako, Glostrup,
Denmark) following the fluorescence profile of 2 2.9.2
2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA)
and APC-H7 probes.Chromatin immunoprecipitation
The process for chromatin immunoprecipitation (ChIP)
has been described in the past [22,23]. Briefly chromatin
was cross-linked with 1.42% formaldehyde and cross-
linking was quenched by addition of 125 mM glycine.
Cells were then harvested in IP buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 5 mM EDTA pH 8, 0.5% NP-40,
1% Triton X-100, 1 mM DDT, 1 mM PMSF, 1 μg/ml
protease inhibitor cocktail (pepstatin, aprotinin, and leu-
peptin), 20 mM β-glycerol phosphate, and 2 mM sodium
orthovanadate). Chromatin was sheared by sonication
(Bioruptor, Denville, NJ, USA) and subjected to immu-
noprecipitation with the indicated antibodies. Precipi-
tated DNA fragments were then amplified in PCR
reactions with specific primers (F’ GAGGAGAGG
CAAGTTTG and R’ AGTCCCTTCGCCTGTTTCTT)
flanking the putative p53 binding sites identified within
the CYP2E1 promoter and analysed by agarose gel
electrophoresis.UPR study using pCAX-HA-2xXBP1deltaDBD9anATG)-
Luc-F construct
The principle of the pCAX-HA-2xXBP1deltaDBD9anATG)-
Luc-F function has been described by Iwawaki and Akai [24].
In brief, stimulation of the ER stress in cells upregulates
UPR by activating the ER signalling proteins PKR-like
endoplasmic reticulum kinase (PERK), activating tran-
scription factor 6 (ATF6) and inositol-requiring enzyme
1 (IRE1). Upon activation, the endoribonuclease activity
of IRE1 catalyses splicing and removal of an intron from
the Xbox binding protein 1 (XBP1) encoding mRNA
thereby allowing its translation into a functional tran-
scription factor [18]. Initiation of UPR and activation of
XBP1 induces luciferase production from the pCAX-
HA-2xXBP1deltaDBD9anATG)-Luc-F reporter whereas
in the absence of UPR the inactive XBP1 is unable to
stimulate luciferase production [24].Scratch wound cell migration assay
The scratch wound assay was performed as described
previously [25]. Briefly coverslips were placed in 6-well
plates and an insert (ibidi, Munich, Germany) was
placed onto the coverslip before cells were seeded. After
ibidi chambers adhered onto the coverslips, 3 × 104 of
MCF7, 3 × 104 of MDA-MB-231 and 6 × 104 of MDA-
MB-157 cells were seeded into each side of the chamber
and incubated overnight at 37°C to subclonfluent stage
and then transiently transfected or treated with different
drugs as indicated. The inserts were then removed from
the coverslips, 2 ml of cell culture medium was added
and cells were incubated at 37°C to allow cell migration
for 16 h for MCF7 and MDA-MB-157, and 8 h for
MDA-MB-231 cells. Subsequent to cell migration, cells
were fixed with 4% paraformaldehyde in PBS for 30 min
at room temperature. After cell fixation, cells were
washed three times with PBS and permeabilised with
Triton (X-100). Anti-β-actin antibody (Abcam, ab8227)
and 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich,
F6057) were used to stain cells.
No patients’ cells/tissues or animals were used in this
study therefore there was no need for ethical approval.
Statistical analysis
Statistical analysis of differences was carried out using
Student’s t test, one-way analysis of variance (ANOVA)
and Tukey’s post hoc test. Values P <0.05 are indicated
with two asterisks and P <0.01 with three asterisks.
Results
CYP2E1 contributes to ROS generation in breast cancer
cells
It has been shown that CYP2E1 is one of the most active
CYP450 isoforms in generating intracellular ROS [26] and
oxygen radicals are associated with cancer development
and metastasis [27]. Several observations link CYP2E1
with inflammatory reactions and carcinogenesis in differ-
ent tissues [28,29] suggesting that CYP2E1 might be
involved in the regulation of tumour growth [29]. To in-
vestigate the role of CYP2E1 in breast cancer, ROS gener-
ation was monitored in MCF7, and MDA-MB-157 cells
treated with ethanol, which is a known CYP2E1 inducer.
In addition, ROS levels were monitored in MCF7, MDA-
MB-231 and MDA-MB-157 cells treated with either the
topoisomerase II inhibitor etoposide, which induces the
transcriptional activity of transcription factors such as p53
and NRF2 which could potentially be involved in the regu-
lation of CYP2E1 gene expression [30,31], the anti-
oxidant NAC or ectopically expressing CYP2E1.
Elevated intracellular ROS levels were observed in
ethanol-treated MCF7 and MDA-MB-157 cells (Figure 1A,
compare bar 3 to bar 1 and bar 4 to bar 2 respectively). In-
creased ROS levels were also recorded in MCF7 and
A B C
Figure 1 Ectopic expression of CYP2E1 induces ROS generation in breast cancer cells. (A) MCF7 and MDA-MB-157 cells were treated with
ethanol and ROS levels were estimated using H2DCFDA and FACS analysis. (B) MCF7, MDA-MB-231 and MDA-MB-157 cells were treated with
etoposide and NAC and ROS levels were estimated as in (A). (C) MCF7, MDA-MB-231 and MDA-MB-157 cells were co-transfected with CD20 and
either PCDNA3 or CMV-CYP2E1 expression plasmid. Subsequent to transfection, cells were treated with H2DCFDA fluorescent stain, and transfected
cells were sorted with an APC-conjugated anti-CD20 antibody and FACS analysis. Data represent fold induction of ROS levels. Error bars indicate
standard deviation obtained from three independent experiments performed in duplicates. Asterisks indicate significant difference at P <0.05. CYP2E1,
cytochrome P450 E1; FACS, fluorescence-activated cell sorting; H2DCFDA, 2 2.9.2 2′,7′-dichlorodihydrofluorescein diacetate; NAC,
N-acetylcysteine; ROS, reactive oxygen species.
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compare bar 4 to bar 1 and bar 5 to bar 2 respectively).
Moderate increase of ROS levels was observed in MDA-
MB-157 cells treated with etoposide (Figure 1B, compare
bar 6 to bar 3). Decreased ROS levels were identified in
MCF7, MDA-MB-231 and MDA-MB-157 cells treated
with the antioxidant reagent NAC (Figure 1B, compare
bars 7, 8 and 9 to bars 1, 2 and 3 respectively). Increased
intracellular ROS levels were also detected in MCF7 and
MDA-MB-231 cells overexpressing CYP2E1 (Figure 1C,
compare black and white bars 2 to black and white bars 1
respectively). Overexpression of CYP2E1 did not signifi-
cantly affect the ROS levels in the MBA-MD-157 cells
(Figure 1C, compare grey bar 2 to grey bar 1).
ROS levels detected by FACS analysis in MCF7, MDA-
MB-231 and MDA-MB-157 cells were a result of CYP2E1
ectopic overexpression as cells transiently transfected with
CYP2E1 expression vector were selected by CD20 co-
transfection as described in the Materials and methods.
Role of CYP2E1 in autophagy
To shed light on the role of the CYP2E1-mediated ROS
generation in breast cancer [14,15] the levels of the au-
tophagic markers beclin-1, LC3, Atg5 and Atg7 were
monitored in MCF7 and MDA-MB-231 breast cancer
cells transiently transfected with CYP2E1 expression
vector or shRNA to silence the CYP2E1 expression.
CYP2E1 ectopic expression in MCF7 cells shown in
Figure 2A (compare lane 2 to lane 1) and CYP2E1 silen-
cing by CYP2E1 shRNA (Figure 2A, compare lane 4 to
lanes 1 and 3) did not have any significant effect onbeclin-1, LC3-2/LC3-1 ratio, Atg5 and Atg7 protein levels
in these cells (Figure 2A, compare lane 2 to lanes 1 and 3).
On the other hand increased beclin-1, LC3-2/LC3-1 ratio,
Atg5 and Atg7 protein levels coincided with CYP2E1 ec-
topic expression in MDA-MB-231 cells (Figure 2B, com-
pare lane 2 to lanes 1 and 3). Reduced protein levels of
these autophagy markers were observed in MDA-MB-231
cells transfected with shRNA against CYP2E1 (Figure 2B,
compare lane 4 to lanes 1 and 3). Western blot analysis of
the autophagic markers in MDA-MB-231 cells lent sup-
port to the notion that autophagy is regulated by CYP2E1
in MDA-MB-231 breast cancer cells.
Role of CYP2E1 in the regulation of the endoplasmic
reticulum stress
Recently published observations have indicated that
CYP2E1 is mainly localised within the endoplasmic
reticulum and functions as metabolic enzyme by oxidis-
ing xenobiotics [32]. Due to their highly reactive proper-
ties, ROS have a short half-life and limited diffusion
distance [33], therefore, they usually inflict cellular dam-
age and impact molecular pathways only near the site of
their production [34]. It is well known that generation of
ROS, sensitisation of ER and initiation of the unfolded
protein response [35] and autophagy are closely related
processes [36,37]. Taken together all the above informa-
tion triggered our interest to explore the potential in-
volvement of CYP2E1 in the regulation of ER stress.
The CYP2E1-mediated ER stress and UPR were
assessed in breast cancer cells by monitoring the luciferase
activity of the pCAX-HA-2xXBP1deltaDBD9anATG)-
A B
Figure 2 CYP2E1 is involved in orchestrating autophagy in breast cancer. MCF7 (A) and MDA-MB-231 (B) breast cancer cells were analysed
for the autophagy biomarkers beclin-1, LC-3, Atg7 and Atg5 protein levels. Cells were transfected with PCDNA3, CMV-CYP2E1 expression plasmid,
scrambled RNAi, and CYP2E1 shRNA and total cell extracts were subjected to western blot analysis. One representative from three independent
experiments is shown. CYP2E1, cytochrome P450 E1; LC-3, light chain 3; shRNA, short hairpin RNA.
Leung et al. Breast Cancer Research 2013, 15:R107 Page 5 of 12
http://breast-cancer-research.com/content/15/6/R107Luc-F reporter in breast cancer cell lines transfected with
PCDNA3, CYP2E1, scrambled RNAi, or CYP2E1 shRNA.
Increased XBP1 splicing was observed in MCF7 cells over-
expressing CYP2E1 (Figure 3A, compare bar 2 to bar 1)
whereas silencing of CYP2E1 expression by CYP2E1
shRNA transfection resulted in pCAX-HA-2xXBP1delta
DBD9anATG)-Luc-F activity similar to that exhibited by
the cells transfected with empty vector or scrambled RNAi
(Figure 3A, compare bar 4 with bars 1 and 3). MDA-MB-
231 cells overexpressing CYP2E1 on the other hand, dis-
played a slight not significant increase of XBP1 splicing
(Figure 3B, compare bar 2 to bar 1) [24]. Evaluation of the
ER stress markers CHOP and GRP78 indicated increased
levels of these proteins in the MCF7 cells transfected with
CYP2E1 expression vector compared to MCF7 cells in
which CYP2E1 expression had been silenced (Figure 3C,
compare lane 2 to lanes 1 and 3 and lane 4 to lanes 1 and
3 respectively). No changes of CHOP and glucose-
regulated protein 78 (GRP78) protein levels were observed
in MDA-MB-231 cells (Figure 3C, lanes 5 to 8).
CYP2E1 modulates cell migration potential
Results shown in Figure 1 provide evidence that CYP2E1
is a potential regulator of intracellular ROS levels in
breast cancer cells. The link between oxidative stress
and metastasis has been demonstrated in several recent
publications [38,39]. Taken together the role of CYP2E1in inducing ROS generation and the fact that CYP2E1 is
differentially expressed in early rather than later stages
of breast cancer [19] implies that this cytochrome P450
isoenzyme might regulate migration of breast cancer
cells. To understand the role of CYP2E1 in these pro-
cesses, the low invasive MCF7 and the highly invasive
MDA-MB-231 as well as the MDA-MB-157 breast can-
cer cells were transiently transfected with CYP2E1 ex-
pressing constructs or vectors silencing the expression
of this enzyme and cell migration was analysed employ-
ing the scratch wound assay.
MCF7 cells overexpressing CYP2E1 displayed reduced
migration capacity compared to those transfected with the
empty vector (Figure 4A and B compare bar 1 to bar 4).
On the other hand, MCF7 cells in which CYP2E1 had
been silenced exhibited increased cell migration compared
to MCF7 cells transfected with PCDNA3 (Figure 4A and
B compare bar 1 to bar 7). Increased migration capacity
was also observed in MDA-MB-231 cells in which
CYP2E1 had been silenced (Figure 4A and B compare bar
2 to bar 8). CYP2E1 overexpression had marginal effect
on the ability of MDA-MB-231 cells to migrate (Figure 4A
and B compare bar 2 to bar 5). Overexpression or silen-
cing of CYP2E1 in MDA-MB-157 cells did not change sig-
nificantly the ability of these cells to migrate compared to
those transfected with PCDNA3 (Figure 4A and B com-
pare bar 3 to bars 6 and 9).
Figure 3 ER stress is induced in MCF-7 and MDA-MB-231 breast cancer cells ectopically expressing CYP2E1. (A) MCF7 and (B) MDA-MB-
231 breast cancer cell lines were transfected with ERAI-Luc and indicated constructs. Cells were harvested and luciferase activity was measured.
Luciferase readings were normalized to the β-galactosidase. Data are representative of three independent experiments. Error bars represent
standard deviation. (C) MCF7 and MDA-MB-231 breast cancer cell lines were transfected with the indicated constructs and submitted to western
blot analysis for the ER stress markers CHOP and GRP78. One representative from three independent experiments is shown. CHOP, CAATienhancer-
binding protein homologous protein; CYP2E1, cytochrome P450 E1; ER, endoplasmic reticulum; GRP78, glucose-regulated protein 78.
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which CYP2E1 gene expression affects cell migration in
breast cancer cells, the migration capacity of untreated,
ethanol, Bort, APAP [40] and the CYP2E1-specific in-
hibitor CMZ-treated [41] MCF7 and MDA-MB-231 cells
was monitored. Ethanol induces CYP2E1 enzymatic ac-
tivity, and Bort is a proteasome inhibitor that has been
shown to induce response to ER stress by stimulating
the accumulation of misfolded proteins in the ER [42].
In accord with results shown in Figure 4, decreased cell
migration was observed in ethanol-treated MCF7 cells
whereas induction of CYP2E1 by ethanol in MDA-MB-
231 cells marginally decreased cell migration (Figure 5B,
compare bar 3 to bar 1 and bar 4 to bar 2 respectively).
Decreased cell migration was observed in APAP- and
Bort-treated MCF7 and MDA-MB-231 compared to
non-treated cells (Figure 5D, compare bars 3 and 5 to
bar 1 and bars 4 and 6 to bar 2). This effect was not
evident in MCF7 and MDA-MB-231 cells treated with
CMZ compared to non-treated cells (Figure 5D,compare bars 7 and 8 to bars 1 and 2 respectively). Re-
sults presented in Figures 4 and 5 revealed that induc-
tion of CYP2E1 reduced the migration capacity whereas
silencing of this CYP450 isoenzyme increased the num-
ber of MCF7 and MDA-MB-231 cells migrating within
the gap indicating that CYP2E1 is potentially involved in
the regulation of the migratory capacity of breast cancer
cells.
CYP2E1 gene expression is under p53 transcriptional
control
The molecular mechanism underlying CYP2E1 induc-
tion has not been clearly elucidated but seems to involve
messenger RNA or protein stabilization and/or tran-
scriptional activation [43]. Taking into account the fact
that the high levels of ROS produced in cells due to the
function of this enzyme could stimulate the transcrip-
tional activity of the cancer-related transcription factor
p53 [44] as well as that decreased CYP2E1 levels
observed throughout cancer progression in different
Figure 4 Ectopic expression of CYP2E1 regulates migration of breast cancer cells. (A) MCF7, MDA-MB-231 and MDA-MB-157 cells were
seeded and incubated with an ibidi culture insert until they reached subconfluent state and then transfected with PCDNA3, CMV-CYP2E1 or
CYP2E1 shRNA plasmids and incubated for further 16 h. The size of the gap was measured after 16 h (MCF7, MDA-MB-157) and 8 h (MDA-MB-
231). (B) Figure represents the calculations of migration distances of cells in (A). Asterisks indicate significant difference at P <0.01. CYP2E1,
cytochrome P450 E1; shRNA, short hairpin rRNA.
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CYP2E1 was a possible p53 transcriptional target.
To test the hypothesis whether higher CYP2E1 cellular
levels in stage I breast tumors compared to stages II, III,
and IV were a result of differential transcriptional regula-
tion of its gene expression and potential involvement of
p53 [46] in this process, we followed the CYP2E1 protein
levels in five different breast cancer cells with different mi-
gratory potential and p53 status, namely MCF7 [20],
T47D [20], MDA-MB-231 [21], MDA-MB-468 and MDA-
MB-157 [20] exposed to either ethanol (MCF7, MDA-
MB-231and MDA-MB-468) or etoposide (etop) (MCF7,
MDA-MB-231, T47D and MDA-MB-157) treatment.
Accumulation of CYP2E1 protein was observed in re-
sponse to ethanol in MCF7, MDA-MB-231 and MDA-
MB-468 cells (Figure 6A, compare lanes 2, 4 and 6 tolanes 1, 3 and 5 respectively) whereas in response to eto-
poside treatment increased CYP2E1 protein levels were
evident in MCF7 and MDA-MB-231 cells (Figure 6B,
compare lanes 2 and 4 to lanes 1 and 3 respectively) and
no significant changes in T47D and MDA-MB-157 cells
(Figure 6B, compare lanes 6 and 8 to lanes 5 and 7 re-
spectively). Reasons explaining the lack of correlation
between the CYP2E1 and p53 protein levels in all cell
lines could be that p53 is not the only transcription fac-
tor that mediates CYP2E1 gene expression and that p53
might be stabilised and accumulated in MDA-MB-231
and T47D cells but it is transcriptionally inactive.
To gain further insight in the transcriptional regula-
tion of the CYP2E1 gene expression and investigate the
potential role of p53 in the regulation of the cellular
levels of this enzyme the luciferase activity of the
A B
C D
Figure 5 CYP2E1 regulates cell migration in breast cancer cell lines. (A) MCF7 and MDA-MB-231 cells were seeded and incubated with an
ibidi culture insert up to subconfluent stage. Cell migration was estimated 16 h (MCF7) and 3 h (MDA-MB-231) after the addition of ethanol.
(B) Figure represents the calculations of migration distances of cells in (A). (C) MCF7 and MDA-MB-231 cells were seeded and incubated as
described in (A). Cell migration was estimated 3 h after the addition of acetaminophen (APAP), 24 h (MCF7) and 8 h (MDA-MB-231) after the
addition of bortezomib (Bort) and 16 h after the addition of chlormethiazole (CMZ). (D) Figure represents the calculations of migration distances
of cells in (C). Asterisks indicate significant difference at P <0.05 (2) and P <0.01 (3). CYP2E1, cytochrome P450 E1.
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ing sites [44] identified in the regulatory region of the
promoter of this gene was studied in MCF-7 breast can-
cer cells. Gradual increase of ectopic expression of p53
resulted in upregulated CYP2E1-Luc reporter activity
(Figure 6C, compare bars 2, 3 and 4 to bar 1). The p53
protein levels were analysed to confirm its ectopic over-
expression (Figure 6B, compare lanes 2, 3 and 4 to lane 1).
Furthermore, to confirm whether the putative p53 binding
sites were functional, the recruitment of p53 to these pu-
tative binding sites was followed in control or treated with
etoposide MCF7 breast cancer cells using ChIP assay. In-
creased occupancy of the CYP2E1 promoter by p53 in the
etoposide-treated compared to the non-treated cells was
observed (Figure 6D, compare lane 2 to lane 1) implying
that p53 is possibly involved in the regulation of CYP2E1
gene expression.Discussion
CYP2E1 is a drug-metabolising enzyme primarily expressed
in hepatocytes, but has also been detected in other tis-
sues including breast, brain, kidney and lungs [3].
CYP2E1 metabolises several pro-carcinogens including
ethanol [7] and, for that reason, most of the research
associated with CYP2E1 focuses on its role in liver dis-
eases [8]. However, its functions in other tissues have
not been extensively studied.
Clinical studies have indicated higher CYP2E1 gene
expression in breast tumours than normal tissues [47]
and decreasing CYP2E1 levels as carcinogenesis pro-
gresses [19] suggesting that this enzyme might serve im-
portant functions in breast carcinogenesis. Given that
CYP2E1 is one of the most active ROS-generating
CYP450 isoforms [7] and considering the link between
oxidative stress and tumour growth we hypothesised that
Figure 6 CYP2E1 gene expression is under the transcriptional control of p53. (A) Breast cancer cell lines MCF7, MDA-MB-231, and MDA-
MB-468 were treated with ethanol and cellular extracts were submitted to western blot analysis with anti-CYP2E1, anti-p53, and anti-β-actin
antibodies. (B) MCF7, MDA-MB-231, T47D and MDA-MB-157 cells were treated with etoposide and total cellular extracts were subjected to
western blot analysis as for (A). (C) CYP2E1-Luc reporter assay in MCF7 cells transfected with increasing amounts of CMV-p53. Data presented as
fold induction of luciferase activity in cells. Results represent the average of three independent experiments. (D) Chromatin immuniprecipitated
using specific p53 monoclonal antibody in non-treated or etoposide-treated MCF7 cells. The pulled-down DNA samples were amplified with PCR
primers targeting CYP2E1 promoter. The resultant PCR product was then submitted to 1% agarose gel electrophoresis and visualised by UV light.
CYP2E1, cytochrome P450 E1.
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carcinogenesis.
In agreement with published observations [7], we de-
tected increased intracellular ROS levels in breast cancer
cells overexpressing CYP2E1 in a manner dependent on
the status of p53. The p53 tumour suppressor plays an
important role in the regulation of the cellular ROS gen-
eration and, in turn, ROS exert positive and negative ef-
fects on the p53 protein stability, transcriptional activity
and gene target selectivity [46]. Low amounts of ROS cor-
relate with stimulation of the expression of anti-oxidant
p53 target genes (glutathione peroxidase 1 (GPX1) [48],
aldehyde dehydrogenase 4 (ALDH4) [49], sestrins 1 and 2
(SESN1 and 2) [50]) and genes involved in the cellular
energy metabolism such as SCO2 (synthesis of cytochrome
c oxidase 2) [51], TIGAR (TP53-induced glycolysis and
apoptosis regulator) [52] and PGM (phosphoglycerate mu-
tase) [53]. The pro-oxidant effects of p53 are mediated by
another set of its target genes such as the p53-induced
gene 3 (PIG3) [54] the p66Shc [55] and the Bcl2 family
members bax and PUMA [50,56]. The mechanisms direct-
ing the p53 target selectivity to antioxidant or pro-oxidant
transcriptional target genes, thereby determining the final
outcome of the p53-mediated cellular redox state, include
posttranslational modifications and recognition of specificDNA binding sites in the regulatory regions of the pro-
moters of pro-oxidant subsets of genes by domains dif-
ferent than the p53 DNA binding domain (proline-rich
domain) [50,54,57] and the affinity of p53 binding to
the promoter of its diverse transcriptional targets fol-
lows a hierarchical order that is dependent on the type
of stress [22,58,59]. In these terms, the amount of
CYP2E1-mediated ROS generation could induce either
antioxidant or pro-oxidant p53 outcomes in a tissue
and cell-type-dependent manner.
Since intracellular ROS levels are closely linked to the
regulation of autophagy, we followed the autophagy bio-
markers beclin-1, LC-3, Atg7 and Atg5 protein levels in
breast cancer cells in which the CYP2E1 was either ec-
topically expressed or silenced. In line with potential
tumour-suppressing function of autophagy, we identified
that the protein levels of the autophagy markers [60,61],
followed the same pattern as that of CYP2E1 in MDA-
MB-231 cells. The role of p53 in linking cellular redox
status energy metabolism and autophagy through transcrip-
tion independent and transcription dependent mechanisms
has been extensively investigated [62-64].
Taking into account the fact that CYP2E1 is predom-
inantly localized in the endoplasmic reticulum [65] as
well as the link between autophagy and ER stress [36,37]
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the ER stress signalling transduction pathway. Integrated
regulation of autophagy, ER stress and unfolded protein
response determines the cell fate in breast cancer [61].
ER stress is able to both inhibit and activate the p53
pathway [66,67]. ER stress in MCF-7 cells stimulates p53
nuclear localization, transcriptional activity and protein
stability through the NF-κB signalling pathway [68]. In
accord with published evidence indicating that CYP2E1
is a positive regulator of UPR [21], our results lent sup-
port to the notion that CYP2E1 induces UPR in MCF7
breast cancer cells transfected with CYP2E1. UPR is al-
tered in many types of cancer [69], including breast can-
cer, and in some cases contributes to chemoresistance
[24,35,70,71], highlighting the importance of our find-
ings for cancer therapy.
The decreasing levels of CYP2E1 in advanced stages of
breast cancer cells [19] together with our observations in-
dicating that high cellular levels of CYP2E1 induce au-
tophagy in MDA-MB-231 cells and UPR in MCF7 cells,
both of which are regulators of the tumour microenviron-
ment [61], led us to investigate its role in regulating mi-
gration of breast cancer cells. To address this question,
migration was followed in breast cancer cells expressing
different levels of CYP2E1. Our results provided evidence
that CYP2E1 expression in breast cancer cells plays a role
in the determination of migratory capacity. In particular,
CYP2E1 ectopic expression inhibited MCF7 and MDA-
MB-231 cell migration whereas CYP2E1 silencing or in-
hibition of its enzymatic activity promoted the ability of
these cells to migrate. Differences in the p53 status be-
tween MDA-MB-231 and MDA-MB-157 cells, as well as
potential defects in the phosphorylation events stabilising
microtubule-associated proteins in a manner involving
CYP2E1-mediated ROS, could explain the difference in
terms of metastasis in the two cell lines. Cytoskeletal
alterations mediated by microtubule-associated proteins
such as members of the tubulin family [72] and the
microtubule-associated protein Tau [73] play an im-
portant role in breast cancer cells’ metastasis and their
cellular levels are affected by p53 [72] and the estrogen
receptor [74,75] status. Another possible mechanism
explaining the effects of the p53-CYP2E1-ROS gener-
ation axis on cell invasion and metastasis could be me-
diated by heparanase, which is a p53 transcriptional
target [76] and is involved in the regulation of the ER
stress-mediated breast cancer cell migration [77], but
this hypothesis requires experimental validation.
To investigate the factors regulating CYP2E1 gene ex-
pression, its protein levels were followed in breast cancer
cells with different p53 and estrogen receptor status
treated with either ethanol, which induces CYP2E1
enzymatic activity, or the topoisomerase II inhibitor eto-
poside, which induces DNA damage and activates p53response. Our results strengthened the hypothesis that
p53 is a possible upstream regulator of CYP2E1 gene
expression.
Taken together, the results presented in this manu-
script provide evidence to suggest that CYP2E1 plays an
important role in breast carcinogenesis and the extent of
the oxidative stress mediated by CYP2E1 determines dis-
tinct p53-mediated effects on autophagy, ER stress and
metastasis in breast cancer cells. Since CYP2E1 overex-
pression restrains migration in the invasive MDA-MB-231
cells, manipulation of CYP2E1 cellular levels could poten-
tially be beneficial for better outcome of late stages of
breast cancer. In addition, since this enzyme is involved in
the metabolism of alcohol, observations described in this
manuscript could be an additional link between chronic
alcohol consumption and breast cancer [78,79].
Conclusions
Ectopic expression of CYP2E1 in breast cancer cells in-
crease ROS generation, modulates autophagy and regulates
ER stress and unfolded protein response in a cell-type-
dependent manner. In addition, induction of CYP2E1 gene
expression is under the transcriptional control of the p53
tumor suppressor and its activation inhibits migration of
the highly invasive MDA-MB-231 breast cancer cells. The
results shown in this manuscript suggest that manipulation
of CYP2E1 protein levels and enzymatic activity could be
potentially exploited in breast cancer therapy.
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